Akiko Chiba1, Rachna Raman2, Alexandra Thomas3, Pierre-Jean Lamy4, Marie Viala4, Stephane Pouderoux4, Sarah L Mott5, Mary C Schroeder6, Simon Thezenas7, William Jacot8. 1. Division of Surgical Oncology, Department of Surgery, Wake Forest University School of Medicine, Winston-Salem, NC. 2. Bon Secours Richmond Heath System, Richmond, VA. 3. Department of Internal Medicine, Wake Forest University School of Medicine, Winston-Salem, NC. 4. Department of Medical Oncology, Institut Régional Du Cancer de Montpellier ICM, Montpellier, France. 5. Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA. 6. College of Pharmacy, University of Iowa, Iowa City, IA. 7. Biometry Unit, Institut Régional Du Cancer de Montpellier ICM, Montpellier, France. 8. Department of Medical Oncology, Institut Régional Du Cancer de Montpellier ICM, Montpellier, France. Electronic address: william.jacot@icm.unicancer.fr.
Abstract
INTRODUCTION: There has been increasing interest in the potential benefit of vitamin D in improving breast cancer outcome. Preclinical studies suggest that vitamin D enhances chemotherapy-induced cell death. We investigated the impact of serum vitamin D levels during neoadjuvant chemotherapy (NAC) on the rates of achieving pathologic complete response (pCR) after breast cancer NAC. PATIENTS AND METHODS: Patients from 1 of 2 Iowa registries who had serum vitamin D level measured before or during NAC were included. French patients enrolled onto a previous study of the impact of NAC on vitamin D and bone metabolism were also eligible for this study. Vitamin D deficiency was defined as < 20 ng/mL. pCR was defined as no residual invasive disease in breast and lymph nodes. A Firth penalized logistic regression multivariable model was used. RESULTS: The study included 144 women. There was no difference between the French and Iowan cohorts with regard to age at diagnosis (P = .20), clinical stage (P = .22), receptor status (P = .32), and pCR rate (P = .34). French women had lower body mass index (mean 24.8 vs. 28.8, P < .01) and lower vitamin D levels (mean 21.5 vs. 27.5, P < .01) compared to Iowan patients. In multivariable analysis, after adjusting for the effects of cohort, clinical stage, and receptor status, vitamin D deficiency increased the odds of not attaining pCR by 2.68 times (95% confidence interval, 1.12-6.41, P = .03). CONCLUSION: Low serum vitamin D levels were associated with not attaining a pCR. Prospective trials could elucidate if maintaining vitamin D levels during NAC, a highly modifiable variable, may be utilized to improve cancer outcomes.
INTRODUCTION: There has been increasing interest in the potential benefit of vitamin D in improving breast cancer outcome. Preclinical studies suggest that vitamin D enhances chemotherapy-induced cell death. We investigated the impact of serum vitamin D levels during neoadjuvant chemotherapy (NAC) on the rates of achieving pathologic complete response (pCR) after breast cancerNAC. PATIENTS AND METHODS: Patients from 1 of 2 Iowa registries who had serum vitamin D level measured before or during NAC were included. French patients enrolled onto a previous study of the impact of NAC on vitamin D and bone metabolism were also eligible for this study. Vitamin D deficiency was defined as < 20 ng/mL. pCR was defined as no residual invasive disease in breast and lymph nodes. A Firth penalized logistic regression multivariable model was used. RESULTS: The study included 144 women. There was no difference between the French and Iowan cohorts with regard to age at diagnosis (P = .20), clinical stage (P = .22), receptor status (P = .32), and pCR rate (P = .34). French women had lower body mass index (mean 24.8 vs. 28.8, P < .01) and lower vitamin D levels (mean 21.5 vs. 27.5, P < .01) compared to Iowan patients. In multivariable analysis, after adjusting for the effects of cohort, clinical stage, and receptor status, vitamin D deficiency increased the odds of not attaining pCR by 2.68 times (95% confidence interval, 1.12-6.41, P = .03). CONCLUSION: Low serum vitamin D levels were associated with not attaining a pCR. Prospective trials could elucidate if maintaining vitamin D levels during NAC, a highly modifiable variable, may be utilized to improve cancer outcomes.
Authors: Song Yao; Lara E Sucheston; Amy E Millen; Candace S Johnson; Donald L Trump; Mary K Nesline; Warren Davis; Chi-Chen Hong; Susan E McCann; Helena Hwang; Swati Kulkarni; Stephen B Edge; Tracey L O'Connor; Christine B Ambrosone Journal: PLoS One Date: 2011-02-28 Impact factor: 3.240
Authors: Hee Jeong Kim; Yu Mi Lee; Beon Seok Ko; Jong Won Lee; Jong Han Yu; Byung Ho Son; Gyung-Yub Gong; Sung Bae Kim; Sei Hyun Ahn Journal: Ann Surg Oncol Date: 2010-12-14 Impact factor: 5.344
Authors: Marissa B Savoie; Alan Paciorek; Li Zhang; Erin L Van Blarigan; Nilli Sommovilla; Donald Abrams; Chloe E Atreya; Emily K Bergsland; Hueylan Chern; Robin K Kelley; Andrew Ko; Angela Laffan; Ankit Sarin; Madhulika G Varma; Alan P Venook; Katherine Van Loon Journal: J Gastrointest Cancer Date: 2019-12
Authors: Marie Viala; Akiko Chiba; Simon Thezenas; Laure Delmond; Pierre-Jean Lamy; Sarah L Mott; Mary C Schroeder; Alexandra Thomas; William Jacot Journal: BMC Cancer Date: 2018-07-30 Impact factor: 4.430
Authors: L J Standish; E Sweet; Eunjung Kim; F Dowd; Ryan McLaughlin; P Chiang; L Dale; M Gaul; M R Andersen Journal: Integr Cancer Ther Date: 2021 Jan-Dec Impact factor: 3.279